Ropes & Gray Advises Cambrex in Acquisition of Avista Pharma Solutions
A cross-practice team of Ropes & Gray attorneys advised Cambrex Corporation in its agreement to acquire Avista Pharma Solutions for approximately $252 million. The deal was announced on Nov. 20.
Cambrex is a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, and Avista Pharma Solutions is a contract development, manufacturing and testing organization. Avista is a portfolio company of Ampersand Capital Partners, a health care focused private equity firm. The acquisition of Avista strengthens Cambrex’s position as a leading fully integrated small molecule contract development and manufacturing organization across the entire drug lifecycle.
The Ropes & Gray team includes securities & public companies associate Thomas Fraser, tax & benefits partner David Saltzman (both of Boston), tax & benefits partner Adam Stella (Washington, D.C.), IP transactions partner Mark Bellomy, real estate partner Peter Alpert, securities & public companies partner Paul Kinsella (all of Boston), life sciences partner Albert Cacozza (Washington, D.C.), and private equity transactions partner Kiran Sharma (London).